irpagratinib

**Irpagratinib** is a highly-selective, small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), designed to block the FGF19-FGFR4 signaling pathway, which is aberrantly activated in a significant subset of patients with hepatocellular carcinoma (HCC)[2][8]. Its mechanism of action involves antagonizing FGFR4, aiming to suppress tumor growth driven by FGF19 pathway overexpression[2][8]. Irpagratinib is being developed and evaluated both as monotherapy and in combination with atezolizumab, an anti-PD-L1 antibody, for the treatment of advanced HCC[2][6][12]. Abbisko Therapeutics, an oncology-focused biopharma company, is the originator and principal developer of irpagratinib[2][8].

Brand names

irpagratinib

Other names

ABSK 011ABSK011ABSK-011